American Journal of Ophthalmology
Volume 148, Issue 6 , Pages 875-882.e1 , December 2009

Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial

  • Manju L. Subramanian

      Affiliations

    • Veterans Affairs Boston Healthcare System, Jamaica Plain, Massachusetts
    • Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts
    • Corresponding Author InformationInquiries to Manju L. Subramanian, Vitreo-retinal Disease and Surgery, Boston University School of Medicine, 85 East Concord Street, 8th Fl, Boston, MA 02118
    • ,
  • Steven Ness

      Affiliations

    • Veterans Affairs Boston Healthcare System, Jamaica Plain, Massachusetts
    • Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts
    • ,
  • Gelareh Abedi

      Affiliations

    • Veterans Affairs Boston Healthcare System, Jamaica Plain, Massachusetts
    • Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts
    • ,
  • Ednan Ahmed

      Affiliations

    • Veterans Affairs Boston Healthcare System, Jamaica Plain, Massachusetts
    • Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts
    • ,
  • Mary Daly

      Affiliations

    • Veterans Affairs Boston Healthcare System, Jamaica Plain, Massachusetts
    • Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts
    • ,
  • Edward Feinberg

      Affiliations

    • Veterans Affairs Boston Healthcare System, Jamaica Plain, Massachusetts
    • Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts
    • ,
  • Sumit Bhatia

      Affiliations

    • Veterans Affairs Boston Healthcare System, Jamaica Plain, Massachusetts
    • Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts
    • ,
  • Payal Patel

      Affiliations

    • Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts
    • ,
  • Maileah Nguyen

      Affiliations

    • Veterans Affairs Boston Healthcare System, Jamaica Plain, Massachusetts
    • ,
  • Antoun Houranieh

      Affiliations

    • Veterans Affairs Boston Healthcare System, Jamaica Plain, Massachusetts

,Accepted 13 July 2009.

References 

  1. Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of age-related eye disease study results: AREDS Report No. 11. Arch Ophthalmol. 2003;121:1621–1624
  2. Brown MM, Brown GC, Sharma S, et al. Age-Related Eye Disease Study Research Group The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol. 2006;17:257–266
  3. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27:331–371
  4. Ho QT, Kuo CJ. Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol. 2007;39:1349–1357
  5. Bhutto IA, McLeod DS, Hasegawa T, et al. Pigment epithelium–derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res. 2006;82:99–110
  6. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40:352–368
  7. Miller JW. Vascular endothelial growth factor and ocular neovascularization. Am J Pathol. 1997;151:13–23
  8. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81:154–162
  9. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–2816
  10. Chakravarthy U, Adamis AP, Cunningham ET, et al. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group Year 2 efficacy results of two randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113:1508–1525
  11. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431
  12. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444
  13. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR Study. Ophthalmology. 2009;116:57–65
  14. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–434
  15. Rosenfeld PJ. Intravitreal Avastin: the low cost alternative to Lucentis?. Am J Ophthalmol. 2006;142:141–143
  16. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035–1047
  17. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology. 2006;113:2002–2011
  18. Steinbrook R. The price of sight—ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355:1409–1412
  19. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg. 1997;13:388–391
  20. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography–guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566–583
  21. Regillo CD, Brown DM, Abraham P, et al. Randomized, double masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239–248
  22. Borenstein M, Rothstein H, Cohen J. Power and precision 2.0: A computer program. Englewood, New Jersey: Biostat; 2004;
  23. Abraham-Marin ML, Cortes-Luna CF, Alvarez-Rivera G, Hernandez-Rojas M, Quiroz-Mercado H, Morales-Canton V. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2007;245:651–655
  24. Aisenbrey S, Ziemssen F, Volker M, et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007;245:941–948
  25. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142:1–9
  26. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol. 2007;143:510–512
  27. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2007;114:1179–1185
  28. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363–372
  29. Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW, Hickey-Dwyer M. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6 and 9 month results. Eye. 2008;22:82–86
  30. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 2007;27:439–444
  31. Madhusudhana KC, Hannan SR, Williams CP, et al. Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. Br J Ophthalmol. 2007;91:1716–1717
  32. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383–390
  33. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495–511
  34. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81–87
  35. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344–1349
  36. Ziemssen F, Luke M, Messias A, et al. Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol. 2008;28:101–109

PII: S0002-9394(09)00505-4

doi: 10.1016/j.ajo.2009.07.009

American Journal of Ophthalmology
Volume 148, Issue 6 , Pages 875-882.e1 , December 2009

Article Tools

* Image Usage & Resolution